Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Breakthrough Therapy Designation

- PMLiVE

AstraZeneca removes R&D and commercial heads

Pascal Soriot's leadership shake-up will see Martin Mackay and Tony Zook leave

- PMLiVE

India could hit Roche and BMS with compulsory licences

Generic versions of Herceptin, Sprycel and Ixempra may reach market before patent expiration

Daiichi Sankyo logo

Daiichi, ArQule cancer drug tivantinib flunks another trial

Fails to meet endpoint in colorectal cancer study

EISAI

Eisai’s farletuzumab fails ovarian cancer trial

Unable to improve progression-free survival

- PMLiVE

Merck suspends Tredaptive worldwide

Trial demonstrates increased risk of serious adverse events

- PMLiVE

Nexavar shows promise in thyroid cancer

Potential new indication for Bayer/Onyx drug

- PMLiVE

Merck drops plans to file Tredaptive in US

Pharma company also says cardiovascular drug should not be prescribed to new patients in Europe

- PMLiVE

Celgene signs $500m antibody deal with Sutro

Joins list of companies with interest in antibody-drug conjugates

- PMLiVE

Fred Powell joins Celator as chief financial officer

Joins oncology specialist from OraPharma

- PMLiVE

Early FDA approval for Ariad’s leukaemia drug Iclusig

Available in US three months ahead of schedule

- PMLiVE

Roche’s Perjeta backed in EU for breast cancer

CHMP recommends use alongside Herceptin

- PMLiVE

AstraZeneca wins stay on Crestor generics in US

Appeals court upholds earlier ruling to validate patent until 2016

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links